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Abstract— Cancer is a chronic disease where cells grow and
multiply in an uncontrollable manner ultimately spreading and
invading surrounding tissue, and metastasising in other parts
or organs of the body. Automata can be used to capture cancer
evolving through a (discrete finite) sequence of progressive
stages called phenotypes. Automata consist of states (known as
hallmarks of cancer) and transitions between states, indicating
a progression or regression of the cancer. We explore extensions
and combinations of different variants of timed automata
and associated tools to model and analyse a model of the
disease in different ways. We combine patient information and
comorbidities with the cancer automaton through composition.
The goal of this work is to use model checking as an analysis
technique to provide further insights into the effectiveness
of treatment plans for a given patient, and how these could
potentially inhibit or slow down the progression of cancer.
I. INTRODUCTION
Cancer is a progressive disease of abnormal cells which
grow and multiply in an uncontrollable manner, ultimately
spreading and invading surrounding tissue and metastasing
in other parts or organs of the body [1].
Cancer’s growth rate varies and can quickly make up to
trillions of cells. Tumours are masses or groups of cells
which appear on solid or liquid tissues and can, in principle,
be either benign or malignant. A tumour is malignant if it
consists of cancerogenous cells. Cancer is a malignant tu-
mour and is dangerous as it can cause death if left untreated.
When cancer grows it can spread and invade nearby tissues
and metastasise.
There are many factors that influence the growth of cancer
such as an unhealthy diet, smoking, physical inactivity,
among others [2]. As the life expectancy of people increases,
cancer also becomes more common. According to [3], about
589,430 Americans are expected to die of cancer in 2015
which amounts to about 1,620 people per day. It is the
second most common cause of death in the US and is
responsible for nearly 1 of every 4 deaths [3]. Similar
statistics can be found in Europe (see1 for the UK). Cancer
research and effective forms of treatment are thus of upmost
importance. Considerable research is done in improving the
understanding of cancer progression. Amongst the efforts
on researching cancer and cancer treatments are cancer
modelling and tumour growth analysis.
Cancer modelling has been addressed in different fields
ranging from applied mathematics to computer simulation.
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In particular, probability models (such as continuous Markov
chains) are widely used to represent tumour growth.
In model checking, systems are modelled as finite state
automata. Automata can be used to capture cancer evolving
through a (discrete finite) sequence of progressive stages
called phenotypes. Cancer Hybrid Automata (CHA) [4] have
been introduced to model the progression of cancer with
discrete phenotypes. It consists of states (aka stages or
hallmarks of cancer) and state transitions indicate cancer
progression or regression. Transitions are labelled by a
treatment (seen as a set of drugs) which if given to the patient
(in a particular dosage) inhibit the transition and hence the
evolution of the cancer. In particular, adding medication
and treatments, a regression of the overall cancer state may
become possible. The idea of an approach such as CHA [4]
is that through verification and analysis of cancer models
we can clarify the effect of a treatment, simulate cancer
evolution and ultimately explore ways (different medications
and treatments) to avoid reaching metastasis. CHA is a con-
ceptual framework based on realistic biological foundations,
but lacks tool support and automated analysis.
The paper is structured as follows. In the next section we
give a brief description of our contribution. In Section III,
we describe an overview of our approach. Section IV briefly
describes some of our models, strategies and model combi-
nations, as well as analysis results. We conclude the paper
with ideas for further work.
II. OUR CONTRIBUTION
The main motivation of our work is to find an alternative
model suitable for capturing cancer progression which solves
some of the problems that CHA [4] currently has. First,
a cancer automaton must include all required information
on possible treatments (for the particular type of cancer)
as known in the medical literature and current practice.
Secondly, the model has to be compositional and as such
make it possible to consider additional patient information
and comorbidities. Comorbidities relate to the presence of
additional diseases other than the primary one which in
our case is cancer [5]. Additional diseases (possibly chronic
ones) cannot be ignored as these may affect certain organs in
critical ways, affect the responsiveness of medications, and
so on. Finally, tool support is essential, and from an analysis
point of view, we focus on:
• How to obtain traces from a cancer automaton cor-
responding to positive treatments, that is, treatments
which show evidence of the cancer being controlled
and possibly even reverted, taking into account any
comorbidity.
• Property verification and model correctness. Properties
are used to compare positive treatments and medications
used by determining the time it takes to revert to an
earlier cancer stage, possible costs or other metrics at
hand.
The specified properties (written in timed and probabilistic
variants of CTL [6]) can help us to compare the effectiveness
of different treatment plans for a given patient, in terms
of how they can inhibit the cancer not just to prevent it
from reaching metastasis but respecting other concomitant
conditions. Examples of properties include it is possible that
metastasis will never be reached (which would correspond
to a path where the treatment is effective), the probability of
cancer cells reaching metastasis in less than 5 years (which
gives a probability value for that scenario), under a certain
cancer treatment the overall liver toxicity always remains
below a certain value, and so on. In particular, we can make
effective comparisons between alternative treatments.
We choose to model breast cancer, and consider different
kinds of treatments/therapies, the size of cancer cells, and
patient comorbidity. We explore how different variants of
timed automata can be useful to capture different notions
and allow us to make different inferences. All the variants
discussed have tool support with advantages and limitations.
We explore the possible combinations of the approaches
which are more suited to provide answers to our questions.
In this way we aim to find the best combination for a cancer
automaton.
III. OUR APPROACH
Our approach models cancer progression using a mech-
anism to determine cancer growth based on the size of
the primary tumour (T), the affected lymph nodes (N), and
the presence of metastasis (M) called TNM Staging [7].
TNM staging has been widely used by physicians to plan
the appropriate treatment for patients as well as estimating
patient prognosis [8]. Our cancer automata are inspired by
CHA but use TNM staging and are based on variants of
timed automata [9] to obtain a (family of) cancer automata.
Timed automata (TA) [9] add the notion of time to
standard automata (based on a finite set of states and labelled
transitions between them) through a set of variables called
clocks. Clocks are special variables which can be inspected
or reset but not assigned a value. A time unit represents a
second, minute or month, depending on what is a sensible
unit for the model. A timing constraint can be placed on
locations (the term used for states in a TA) to denote a
location invariant (to indicate for instance how long the
automaton can remain in the location) and on transitions
where it acts as a guard. Although TA are very useful to
model real-time systems, additional notions such as energy,
memory consumption, band-width, cost, etc, cannot be cap-
tured directly. Priced or weighted timed automata (PTA) [10]
have been introduced for this purpose and have additional
special clock variables to capture time dependent quantities
such as cost. In addition to cost, many real-life systems show
stochastic behaviour (e.g., unreliable communication media
due to bad weather, component failures, etc). This form
of non-determinism is vital for many systems. Probabilistic
Timed Automata (ProTA)[11] add probabilities to transitions.
To also address real-time systems operating under uncon-
trollable environments, a further variant of timed automata
was introduced called Timed Game Automata (TGA) [12]. A
timed game can provide an algorithm that makes it possible
to generate an adaptive strategy for both best and worst case
scenarios caused by the system environment.
Cancer automata borrow the notions of time constraint,
clock, and location invariant and use them to encode the
properties to determine the progression of cancer. In general,
an automaton consists of a finite set of locations which
for a cancer automaton is restricted to the four locations
associated to cancer TNM stages, where the last stage
corresponds to metastasis. We also consider a further location
to indicate when sufficient time has passed for the patient
to be considered cancer free. Transitions are used to model
the therapies and treatments for each stage, while location
invariants are being used to determine the progression of
cancer. Through verification of a cancer automaton (possibly
in composition with additional automata for capturing other
key aspects of a patient including any concomitant condi-
tions), it is possible to select and evaluate amongst several
treatments with respect to overall benefits (e.g., less impact
on concomitant conditions) or other factors such as cost.
Fig. 1. Cancer automata framework
Our approach starts with Priced Timed Cancer Automata
(PTCA) which is closest to the original timed CHA but
with some modifications and contains a way of capturing
cost (see Fig. 1). We then add more properties of cancer
(e.g. tumour size, affected lymphatic nodes (NX)) as location
invariants. We create a Probabilistic Timed Cancer Automata
(ProTCA) by adding probabilities and removing the cost
property. We combine both PTCA and ProTCA to obtain
a Priced Probabilistic Timed Cancer Automata (PPTCA).
Similarly, we add uncertainty into the PTCA model to obtain
a Timed Game Cancer Automata (TGCA). Using TGCA, we
are interested in finding a strategy which avoids metastasis
without considering cost. Lastly, we obtain a new Probabilis-
tic Timed Game Cancer Automata (PTGCA) by combining
both TGCA and PTGCA. With this model, we hope to
decrease the uncertainty in accordance to the properties we
have considered. The PTGCA has both branching transitions
and uncontrollable transitions. In this model, a therapy may
or may not improve the patient’s condition. The likelihood
of delaying or facilitating cancer progression is unknown.
IV. CANCER ANALYSIS THROUGH MODEL CHECKING
We have used several variants of timed automata to ex-
plicitly explore different properties, concerns and associated
tools when modelling (breast) cancer. These models allow us
to separate different aspects which when combined result in
a more expressive but more complex model. We reflect on
the results of the analysis for PTCA, ProTCA, and PPTCA2.
A. Priced Timed Cancer Automata (PTCA)
In this automaton, locations represent the stages of cancer,
and transitions model cancer therapies. A therapy is repre-
sented by a transition that modifies the value of a global
double variable rate. How the value of rate changes depends
on the therapy associated to the transition. If a medication is
effective it delays the progression of cancer. Decreasing the
(growth) rate at a particular location (cancer stage) models
a delay of the cancer growth. Each transition has a cost
property that gradually increases and models the resources
needed in order to perform the therapy. These cost properties
contribute to the total cost value of the system. The increment
depends on whether it has previously been applied to the
patient as well as the progression of cancer (i.e. the higher the
stage, the higher the cost property). In addition to locations
that denote the stages of cancer, we have another location
to represent a state where the treatment has been successful
and it is possible to refer to a cancer free state (CanFree).
The goal of the PTCA model is to find the optimal
cost to reach CanFree which can be specified in CTL by
∃♦CanFree (there exists a path where eventually the location
CanFree is reached). If existing, the optimal path is shown.
Fig. 2. Tumour Growth Case No. 1
B. Probability Timed Cancer Automata (ProTCA)
We extend our cancer model by considering more proper-
ties (e.g. tumour size, affected lymphatic nodes), which give
us more accurate information on the stage of cancer. Our
2See https://juliana.host.cs.st-andrews.ac.uk/CancerAutomata/ for details.
ProTCA models the cancer growth by using its tumour size
and the spreading to nearby lymphatic nodes as the location
invariants. To begin with, we have an integer variable logD
to determine the size of the tumour in logarithmic scale. We
use the tumour size of a patient data (i.e Case No. 1) in [13].
Fig. 2 plots the exponential growth of the tumour size.
To simplify the modelling of the tumour growth, we scale
the growth logarithmically. We perform a linear regression
to get the polynomial equation for our ProTCA (i.e. size =
0.041072500921616864∗ time+1.4017231839892936). We
then scale (i.e. by factor 100) and round the equation to
implement it in our model. Then, we create an action
setGrowth() in our ProTCA to simulate the growth. Our
ProTCA model is too large to be shown here. The main idea
is that since the success rate of a therapy is not exact [14],
we use branching weight probabilities to express therapy
effectiveness.
To take into account patient comorbidities [5], we can, for
instance, model the levels of toxicity of the liver in a separate
automaton. Liver toxicity is affected by external factors (e.g.,
additional medication) which may force transitions in the
liver automaton. Conversely, if the liver has high toxicity,
some therapies cannot be given because toxicity levels act
as guards for some of the transitions in the cancer automaton.
C. Priced Probabilistic Timed Cancer Automata (PPTCA)
After we model the ProTCA, we reintroduce the cost
property to the model. We assign a particular cost value to
each therapy based on their effectiveness (as in the PTCA).
The value denotes the resources needed for treating cancer
(e.g. financial cost, method of treatment, medications).
The obtained PPTCA is an extension of the ProTCA
with an additional cost property. We add further so-called
strategy templates to model an appropriate set of actions
to be performed in each stage of cancer. A strategy is a
simple timed automaton which synchronises with the main
cancer automaton through channels. A strategy can show
alternatives if some therapies cannot be applied to the patient
because of the comorbidity factor.
D. PPTCA Properties
To verify the PPTCA, we use logics TCTL and PCTL.
We observe the estimation of the expected minimum and
maximum value of the cost needed to perform a particular
strategy. Each combination of strategies is monitored and
compared. Next, we simulate the tumour growth, the affected
lymphatic nodes (NX), the metastasis stage (Stage4), as
well as the liver comorbidity. Some of our properties for the
PPTCA are shown in Table I. Each query in Table I has been
verified for all strategies. We are interested in comparing the
cost and success rate of each strategy to avoid metastasis.
Through verification, we are able to compare some quan-
titative properties for each strategy. Further, we want to
compare how optimal strategies are. The comparison is
shown in both Fig. 3(a) and Fig. 3(b).
Fig. 3(a) shows the effectiveness of each strategy to




EG¬Stage4 There exists a path where metastasis
is never reached.
P (Fxrm≤300Stage4) The probability of cancer cells reach-
ing metastasis in less than 25 years.
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Plotting Metastasis and affected lym-
phatic nodes. We multiply Stage4
by 3 for easier observation.
(a) Strategy Cost-Effectiveness (b) Strategy Effectiveness-Risk
Fig. 3. Strategy Comparison
each strategy. Although, Fig. 3(a) shows an upward trend in
the probability of avoiding metastasis towards the cost (i.e.
the higher the cost, the higher the probability of avoiding
metastasis), this statement is not necessarily true. First of
all, we need more data and strategies to correctly determine
the relation between the cost property and the effectiveness
of a strategy. However, adding more therapies may lead to
the state-space explosion problem. To avoid the state-space
explosion problem we can add only a subset of therapies
used in the strategy to the PPTCA model (basically do the
analysis in stages).
Fig. 3(b) shows the effectiveness of therapies against
patient comorbidity (here only liver toxicity). From the
strategy comparison shown in both Fig. 3(b) and Fig. 3(a), it
is possible to choose a strategy based on patient preferences.
We have also considered other cancer progression character-
istics such as the spreading of cancer to the lymphatic nodes
before metastasis, tumour growth, but we omit details here.
V. CONCLUSION
Our main goal was to explore the suitability of model
checking as an automated technique to build a framework
to quantify the suitability and effect of different treatment
options for a specific patient with potential comorbidities. To
have access to existing verification tools, we explored a new
family of cancer automata obtained by extending variants of
timed automata. Our models include different properties and
information about cancer progression. By using branching
weighted probabilities, for instance, we can model the prog-
nosis rate [8] to some extent. Branching probabilities can be
useful to model the effectiveness of a therapy towards the
inhibition of cancer growth in comparison to a controlled
transition. In addition, we introduced strategies, such as
applying different therapies or medication based on cancer
progression and comorbidity (i.e. liver toxicity), to give an
idea of a treatment’s effectiveness and possible risks.
Longitudinal data sets can be used to give real accurate
values and probabilities to our model, making our framework
more valuable and realistic. Breast cancer is one example
where longitudinal data sets exist. Relevant work at this level
is given in [15] where real data has been used to inform
Markov-based models. This work shows how predicting the
progression of metastatic cancer may contribute to chances of
survival. Finally, we want to add more properties of cancer to
our model and work closely with oncologists to understand
the overall benefit of the approach.
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